GenTide Biotech is an international innovative drug enterprise powered by an AI Bio-Large Model Platform. We integrate AI with Cryo-EM structural biology to discover first-in-class therapies in metabolic disease, pain, oncology, and aging. 睿联生物科技是一家以AI生物大模型平台为核心发动机的国际化创新药企业。 我们深度融合人工智能与冷冻电镜结构生物学，在代谢疾病、疼痛管理、 肿瘤治疗与抗衰老领域开发 first-in-class 创新药。
Explore the Platform 了解技术平台 View Pipeline 查看研发管线Our AI-driven DTBL closed-loop compresses drug discovery timelines while improving the chances of delivering a viable clinical candidate. 我们的 AI 驱动的 DTBL 研发闭环大幅缩短新药发现周期， 同时显著提升临床前候选化合物的命中率与成药性。
GenTide's edge is not a software stack — it is the combination of deep biological insight and AI that makes each other sharper. Our algorithms are built on published research. Our models are trained on real structural data. Our hypotheses are tested in actual cells and in-vivo. 睿联的竞争力不是一套软件栈——而是深度生物学洞察与 AI 的结合，二者互相磨砺、相互增益。 我们的算法建立在已发表的研究之上。我们的模型用真实结构数据训练。 我们的假设在真实细胞和体内模型中验证。
NBI, SGEDiff, ComplexDnet — models developed from first-principles structural biology research, not fine-tuned generalist LLMs. NBI、SGEDiff、ComplexDnet——从第一性原理结构生物学研究中发展而来的模型，而非通用 LLM 微调。
Atomic-resolution structural validation in-house — not outsourced. Each structure solved feeds directly back into the next generation of AI models. 原子分辨率结构验证在内部完成，不外包。每一张解析的结构直接反馈到下一代 AI 模型。
Every platform investment is justified by its ability to produce better drug candidates faster. We build what we need to win. 每项平台投资都以能否更快产出更好的候选药物为衡量标准。我们只构建赢所必需的能力。
10+ core algorithms and a 10M+ compound library drive source-innovation and a high-druggability chemical space. 10+ 核心算法与千万级分子库，驱动源头创新， 构建高成药性化学空间。
Novel PAGln/PAA pro-aging mechanism backed by Nature Aging publications and proprietary p16 reporter mice. 揭示全新 PAGln/PAA 促衰老致病机制， 发表于 Nature Aging，依托独家 p16 报告基因小鼠。
Seamless dry-wet experiment synergy solves the high trial-and-error cost of traditional drug discovery. 干湿实验无缝协同，破局传统新药发现试错成本极高的行业痛点。
US / Singapore / China global layout with full NMPA + FDA dual IND filing capability. 美国 / 新加坡 / 中国全球布局， 具备 NMPA 与 FDA 中美双报核心能力。
GLP-1R / GIPR / GCGR tri-agonist for metabolic disease and obesity. GLP-1R / GIPR / GCGR 三靶点激动剂，靶向代谢疾病与肥胖。
Nav1.8 selective inhibitor — safer pain management without addiction risk. Nav1.8 选择性抑制剂，消除成瘾风险的安全镇痛方案。
MET / RET / ROS1 allosteric inhibitor with AI conjugates to overcome resistance. 针对 MET / RET / ROS1 的变构抑制剂，AI 偶联突破耐药。
β2-AR original mechanism with PAGln/PAA validation loop. β2-AR 原创机制，PAGln/PAA 促衰老验证闭环。
GenTide runs a dual-track model — pipeline assets plus platform services — so early-stage milestones generate real cash flow while the major programs advance. GenTide 采用"管线资产 + 平台服务"双轨模式，让早期里程碑即产生真实现金流， 同时推动核心管线持续前进。
Open the DTBL + Cryo-EM platform to pharma partners under a fee-plus-milestone model. Stable early cash flow while validating platform value and building License-out relationships. 向大型药企开放 DTBL + 冷冻电镜平台，收取服务费 + 里程碑费用。 早期最稳定的现金流来源，同时验证平台价值，为后续授权铺路。
At PCC or IND stage, license regional rights to big pharma for upfront + milestone + royalties. Nav1.8 is the leading License-out candidate targeting US/EU rights. Target: ¥80M–120M near-term, ¥500M–800M mid-term. 在 PCC 或 IND 节点将地区权益授权给大药企，收取预付款 + 里程碑 + 销售分成。 Nav1.8 为首要 License-out 候选。近期目标 8,000 万—1.2 亿元，中期 5—8 亿元。
Retain Greater China rights, partner with US/Europe for co-funded clinical development. Shared risk, shared upside — without diluting our core China market position. 保留大中华区权益，与美国 / 欧洲合作伙伴联合资助临床开发。 风险共担、收益共享，同时保留中国市场核心地位。
Core team assembled · DTBL data pipeline live · GLP-1 & Nav1.8 in-vitro positive data核心团队到位 · DTBL 数据管道上线 · GLP-1 & Nav1.8 体外阳性数据
GLP-1 PCC confirmed · Nav1.8 in-vivo validation · β2-AR PCC announced · DTBL first full closed-loopGLP-1 PCC 确认 · Nav1.8 体内验证阳性 · β2-AR PCC 宣布 · DTBL 首次完整闭环
GLP-1 & Nav1.8 IND-enabling studies launched · First CMC filing drafted · TKI PCC confirmedGLP-1 & Nav1.8 IND 使能研究启动 · 首份 CMC 文件起草 · TKI PCC 确认
Nav1.8 + GLP-1 IND approved (NMPA & FDA dual-track) · Nav1.8 first License-out LOI signedNav1.8 + GLP-1 双 IND 获批（中美双轨）· Nav1.8 首个 License-out LOI 签署
Nav1.8 Phase I enrollment begins · GLP-1 Phase I starts · Major License-out deal closedNav1.8 I 期首例入组 · GLP-1 I 期启动 · 首个重大 License-out 完成
Nav1.8 Phase I/II data · GLP-1 Phase II designed · β2-AR clinical path definedNav1.8 I/II 期数据读出 · GLP-1 II 期方案设计 · β2-AR 临床路径明确